Non-reactive Acrylic Polymer Matrix for Methylphenidate Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal methylphenidate delivery compositions face challenges in achieving suitable physical and pharmacokinetic properties, leading to issues such as 'tight release' and reduced effectiveness due to degradation from reactive functional groups.
Innovation Solution
A flexible transdermal delivery system comprising a polymer matrix of methylphenidate or its pharmaceutically acceptable salt combined with non-reactive acrylic polymers, specifically formulated with monomers like methyl acrylate and 2-ethylhexyl acrylate, which avoids reactive interactions and ensures stable drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If reactive functional groups are used in the polymer matrix, then adhesion and flexibility may be improved, but drug degradation occurs and therapeutic effectiveness is reduced
Solution Approach 1:
The patent removes reactive functional groups (carboxyl, hydroxyl, amine, thiol, silanol) from the polymer matrix composition that cause drug degradation. By extracting these harmful reactive components and replacing them with non-reactive alternatives, the system maintains adhesion and flexibility while preventing methylphenidate degradation, thus resolving the contradiction between adhesion improvement and drug stability.
Solution Approach 2:
The patent converts the potential harm of reactive functional groups into a benefit by using their absence as a design feature. The non-reactive nature of the polymer matrix becomes the key advantage that prevents drug degradation while still providing necessary adhesion and flexibility through alternative chemical compositions and formulations.
2Reliability
If the polymer matrix formulation is optimized for drug stability, then 'tight release' is avoided, but achieving suitable pharmacokinetic properties becomes more challenging
Solution Approach 1:
The patent optimizes multiple parameters of the polymer matrix system including the specific composition of non-reactive polymers, the ratio of adhesive to non-adhesive polymer, the inclusion of plasticizers, and the molecular weight distribution. These parameter changes enable the system to achieve both drug stability (avoiding tight release) and suitable pharmacokinetic properties for effective transdermal delivery.
Solution Approach 2:
The patent employs a composite polymer matrix system combining multiple non-reactive polymers with complementary properties. This composite approach allows the system to simultaneously provide drug stability, appropriate adhesion, flexibility, and controlled release kinetics, resolving the contradiction between reliability and productivity in drug delivery.
3Reliability
If non-reactive acrylic polymers are used to prevent drug degradation, then drug integrity is maintained, but adhesive properties may be reduced
Solution Approach 1:
The patent segments the polymer matrix into distinct functional components: non-reactive adhesive polymers for drug delivery and skin adhesion, and separate non-reactive non-adhesive polymers for providing flexibility and preventing drug degradation. This segmentation allows each component to optimize its specific function while working together in the composite matrix system.
Solution Approach 2:
The patent applies local quality by creating regions within the polymer matrix with different properties. The adhesive polymer components provide localized adhesion at the skin interface, while non-reactive components provide localized drug protection in the bulk matrix, allowing both drug integrity and adhesion to be optimized in their respective zones.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a therapeutically effective and stable transdermal delivery of methylphenidate over 8-12 hours with improved adherence and ease of use, avoiding the 'tight release' issue and maintaining drug integrity, as demonstrated by comparable pharmacokinetic profiles to commercial products like Daytrana®.
Implementation Method 1
at least one acrylic polymer that is non-reactive with methylphenidate
Implementation Method 2
transdermal delivery of methylphenidate... deliver methylphenidate over a period of time of at least about 8-12 hours
Data Source
AI summary
Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described.